Association of Plasma Soluble Urokinase Plasminogen Activator Receptor Concentrations and Migraine with Aura: a REFORM Study

Overview

Journal Brain Commun

Publisher Oxford University Press

Specialty Neurology

Date 2025 Feb 18

PMID 39963289

Authors

Betel Tesfay

Hakan Ashina

Rune Hackert Christensen

Haidar M Al-Khazali

William Kristian Karlsson

Faisal Mohammad Amin

Baker Nawfal Jawad

Ove Andersen

Messoud Ashina

Affiliations

Soon will be listed here.

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) has garnered attention as a potential blood-based biomarker for low-grade chronic inflammation. However, its specific association with migraine, including its subtypes, remains to be elucidated. We sought to examine the association of plasma suPAR levels with migraine and its subtypes. In this single-centre, cross-sectional study, plasma was collected at a single time point in adults with migraine and sex-matched healthy controls from October 2020 to June 2022. The quantification of plasma suPAR levels was performed in a blinded fashion using a validated enzyme-linked immunosorbent assay. Plasma suPAR levels were compared between participants with migraine (including subgroups) and healthy controls. Plasma samples were analysed from 634 eligible participants with migraine [mean (SD) age, 44.0 (12.2) years; 568 (89.6%) females] and 154 healthy controls [mean (SD), 41.3 (11.8%) years; 132 (86%) females]. Plasma suPAR levels were 6.7% higher (95% CI: 0.1-13.6%; = 0.045, adjusted for age, sex, body mass index and smoking) in participants with migraine aura, when compared with healthy controls. Further analysis revealed no difference in plasma suPAR levels between the overall migraine group and healthy controls (3.7%; 95% CI: -0.7-8.2%; = 0.097), as well as between participants with migraine without aura and healthy controls (2.5%; 95% CI: -2.9-8.3%; = 0.81). Similarly, plasma suPAR levels did not differ across participants with episodic migraine, chronic migraine and healthy controls. Finally, we found no difference when comparing participants with migraine at time of blood sampling with participants with non-migraine headache (1.0%; 95% CI: -5.7-8.2; > 0.99), participants without headache (1.2%; 95% CI: -4.2-7.0%; > 0.99) or healthy controls (4.5%; 95% CI: -1.9-11.3%; = 0.39). Elevated plasma suPAR levels in migraine with aura indicate the presence of low-grade chronic inflammation. Future research should explore the role of suPAR in the neurobiologic underpinnings of migraine with aura.

References

Neeb L, Hellen P, Boehnke C, Hoffmann J, Schuh-Hofer S, Dirnagl U . IL-1β stimulates COX-2 dependent PGE₂ synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011; 6(3):e17360. PMC: 3048859. DOI: 10.1371/journal.pone.0017360. View

Jander S, Schroeter M, Peters O, Witte O, Stoll G . Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J Cereb Blood Flow Metab. 2001; 21(3):218-25. DOI: 10.1097/00004647-200103000-00005. View

Schain A, Melo-Carrillo A, Borsook D, Grutzendler J, Strassman A, Burstein R . Activation of pial and dural macrophages and dendritic cells by cortical spreading depression. Ann Neurol. 2018; 83(3):508-521. PMC: 5965700. DOI: 10.1002/ana.25169. View

Kurth T, Ridker P, Buring J . Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2007; 28(1):49-56. DOI: 10.1111/j.1468-2982.2007.01467.x. View

Grinberg Y, Dibbern M, Levasseur V, Kraig R . Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-α responses to spreading depression. J Neurochem. 2013; 126(5):662-72. PMC: 3752330. DOI: 10.1111/jnc.12267. View

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

Strassman A, Raymond S, Burstein R . Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996; 384(6609):560-4. DOI: 10.1038/384560a0. View

Czekay R, Aertgeerts K, Curriden S, Loskutoff D . Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003; 160(5):781-91. PMC: 2173358. DOI: 10.1083/jcb.200208117. View

Moskowitz M . Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43(6 Suppl 3):S16-20. View

10.

Portelli M, Moseley C, Stewart C, Postma D, Howarth P, Warner J . Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients. Allergy. 2016; 72(3):473-482. DOI: 10.1111/all.13046. View

11.

Kim Y, Kim M, Choi S, You S, Yoo R, Kang K . Altered Vascular Permeability in Migraine-associated Brain Regions: Evaluation with Dynamic Contrast-enhanced MRI. Radiology. 2019; 292(3):713-720. DOI: 10.1148/radiol.2019182566. View

12.

Hougaard A, Amin F, Christensen C, Younis S, Wolfram F, Cramer S . Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017; 140(6):1633-1642. DOI: 10.1093/brain/awx089. View

13.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen T, Langkilde A . Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010; 268(3):296-308. DOI: 10.1111/j.1365-2796.2010.02252.x. View

14.

Enger R, Tang W, Vindedal G, Jensen V, Helm P, Sprengel R . Dynamics of Ionic Shifts in Cortical Spreading Depression. Cereb Cortex. 2015; 25(11):4469-76. PMC: 4816793. DOI: 10.1093/cercor/bhv054. View

15.

Cinque P, Nebuloni M, Santovito M, Price R, Gisslen M, Hagberg L . The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol. 2004; 55(5):687-94. DOI: 10.1002/ana.20076. View

16.

Zetterberg H, Burnham S . Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain. 2019; 12(1):26. PMC: 6437931. DOI: 10.1186/s13041-019-0448-1. View

17.

Button K, Ioannidis J, Mokrysz C, Nosek B, Flint J, Robinson E . Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013; 14(5):365-76. DOI: 10.1038/nrn3475. View

18.

Edvinsson L, Haanes K, Warfvinge K . Does inflammation have a role in migraine?. Nat Rev Neurol. 2019; 15(8):483-490. DOI: 10.1038/s41582-019-0216-y. View

19.

Olmos G, Llado J . Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators Inflamm. 2014; 2014:861231. PMC: 4055424. DOI: 10.1155/2014/861231. View

20.

Garcia-Monco J, Coleman J, Benach J . Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 2002; 129(1-2):216-23. DOI: 10.1016/s0165-5728(02)00186-8. View